Akebia Therapeutics vs Heron Therapeutics
AKBA and HRTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and HRTX compare
Akebia Therapeutics is the larger company, worth 2.2 times as much as Heron Therapeutics ($131M against $58.9M).
Heron Therapeutics grew revenue faster over the last twelve months (−4.4% versus −12.4% for Akebia Therapeutics).
Heron Therapeutics keeps more of each dollar of sales as profit, with a net margin of −14.5% compared with −22.6% at Akebia Therapeutics.
Heron Therapeutics scores higher on the StockData Score (8 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | HRTX |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $58.9M |
| Share price | $0.474 | $0.310 |
| Change, 1 year | −74.4% | −72.0% |
| Change, 5 years | −82.9% | −96.9% |
| Beta (5Y) | 1.10 | 1.79 |
| Employees | 194 | 128 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 2 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× | 0.4× (better) |
| P/B | 6.5× (better) | 12.0× |
| P/FCF | 9.5× | – |
| FCF yield | 10.5% (better) | −24.4% |
| Growth | ||
| Revenue growth (TTM) | −12.4% | −4.4% (better) |
| Revenue growth, 5Y average | −4.3% | 11.8% (better) |
| Profitability | ||
| Gross margin | 78.9% (better) | 71.5% |
| Operating margin | −15.7% | −5.7% (better) |
| Net margin | −22.6% | −14.5% (better) |
| FCF margin | 7.0% (better) | −9.7% |
| Return on equity | −144% (better) | −218% |
| Financial health | ||
| Debt / equity | 2.47 (better) | 0.00 |
| Current ratio | 1.36 | 2.33 (better) |
| Altman Z-score | −6.30 (better) | −10.60 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.7% | 70.4% |
| Held by insiders | 2.9% | 21.6% |
| Insider net buying, 12 months | −$876K | – |
| Short interest, % of float | 10.1% | 22.8% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- HRTX stock overview
- HRTX income statement
- HRTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.